ADVERTISEMENT Do you want your own advert here? Advertise with us!

More News! Big Money for a Danish CRO, a Bad Opinion for a Swiss Pharma

15/09/2017 - 2 minutes
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
  • Boehringer Ingelheim committed €250M to Danish CRO Gubra in a diabetes deal

  • Sanofi got a slight nod from the FDA for its a biosimilar of Humalog, Eli Lilly’s best-selling insulin
  • Anergis scored a marginal win — 7% improvement — in a Phase IIb designed to test the efficacy of its allergy immunotherapy
  • Santhera’s repurposed Duchenne muscular dystrophy drug, Raxone, got hit with a negative CHMP opinion questioning its efficacy
  • AB Science also suffered a slap from CHMP: the French biotech had requested the reassessment of masitinib in indolent systemic mastocytosis, but the committee was not convinced of a favorable risk-benefit ratio
  • Moderna and its partner, AstraZeneca, have let more light in to show off a newly reorganized R&D structure
  • There’s a new biotech on the Leiden block: TM3 has debuted with a Nature publication as a biotech developing metabolite replacement therapies
  • Finland-based BC Platforms joined forces with Microsoft Genomics to launch a platform to integrate genomic and clinical data
  • Inotrem has a new lead compound in septic shock that just turned up positive preclinical results

Images via nattanan726, kunanon, hkhtt hj, Seregraff / shutterstock.com


Support Us

Become a Member